Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

Next Previous
Trial Profile

A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Sunitinib
  • Indications Cancer metastases; Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms IMmotion151
  • Sponsors Chugai Pharmaceutical; Genentech; Roche

    • Most Recent Events

    • 06 Jun 2023 Results describing the development and optimization of a machine learning model for assigning individual patients to biologically driven clusters in real time to facilitate RNA-seq based biomarker trials presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 19 Feb 2022 Data from studies (CheckMate 214, Keynote 426, Javelin Renal 101, CheckMate 9ER, Immotion 151, and CLEAR ) used to perform a cost effectiveness analysis of six recently approved IO-TKI drug combinations and sunitinib presented at the 2022 Genitourinary Cancers Symposium
    • 20 Jan 2022 This trial has been completed in Poland (Date of the global end of the trial : 13-Dec-2021), according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top